TY - JOUR
T1 - Immunogenic and tolerogenic cell death
AU - Green, Douglas R.
AU - Ferguson, Thomas
AU - Zitvogel, Laurence
AU - Kroemer, Guido
N1 - Funding Information:
L.Z. and G.K. are supported by grants from the Ligue Nationale contre le Cancer, the European Union (ALLOSTEM, DC-THERA for L.Z.; Active p53, ApoSys, ApopTrain, RIGHT for G.K.), Fondation pour la Recherche Médicale, Cancéropôle Ile-de-France, Institut National du Cancer and Agence Nationale pour la Recherche. T.A.F. is supported by National Institutes of Health (NIH) grants EY06765, EY15570, and the Department of Ophthalmology and Visual Sciences core grant (EY02687). Support was also received from the Foundation for Fighting Blindness (Owings Mills, Maryland, USA), Research to Prevent Blindness (New York, USA), and the Macular Vision Research Foundation (West Conshohocken, Pennsylvania, USA). D.R.G. is supported by grants from the NIH and by the American Lebanese and Syrian Associated Charities.
PY - 2009/5
Y1 - 2009/5
N2 - The immune system is routinely exposed to dead cells during normal cell turnover, injury and infection. Mechanisms must exist to discriminate between different forms of cell death to correctly eliminate pathogens and promote healing while avoiding responses to self, which can result in autoimmunity. However, an effective immune response against host tissue is often needed to eliminate tumours following treatment with chemotherapeutic agents that trigger tumour cell death. Consequently, a central problem in immunology is to understand how the immune system determines whether cell death is immunogenic, tolerogenic or 'silent'.
AB - The immune system is routinely exposed to dead cells during normal cell turnover, injury and infection. Mechanisms must exist to discriminate between different forms of cell death to correctly eliminate pathogens and promote healing while avoiding responses to self, which can result in autoimmunity. However, an effective immune response against host tissue is often needed to eliminate tumours following treatment with chemotherapeutic agents that trigger tumour cell death. Consequently, a central problem in immunology is to understand how the immune system determines whether cell death is immunogenic, tolerogenic or 'silent'.
UR - http://www.scopus.com/inward/record.url?scp=67349124914&partnerID=8YFLogxK
U2 - 10.1038/nri2545
DO - 10.1038/nri2545
M3 - Review article
C2 - 19365408
AN - SCOPUS:67349124914
SN - 1474-1733
VL - 9
SP - 353
EP - 363
JO - Nature Reviews Immunology
JF - Nature Reviews Immunology
IS - 5
ER -